title: Impact of Helicobacter pylori infection on severity of psoriasis and response to treatment.
abstract: The aims of this study were to determine the prevalence of H. pylori seropositivity in patients with psoriasis, to evaluate the relationship between PASI (Psoriasis Area and Severity Index) scores and H. pylori infection, and to assess the impact of H. pylori infection on the response to treatment. A total of 300 patients with psoriasis and 150 non-psoriatic healthy controls were enrolled in the study. Patient PASI scores were recorded and H. pylori stool antigen tests performed in both patients and controls. Fifty patients with H. pylori infections were randomly assigned to one of two groups, one of which received acitretin with H. pylori treatment and the other acitretin alone. Statistical analyses were performed using chi-square and logistic regression tests. PASI scores were significantly higher in patients with H. pylori infections. Treatment aimed at eradicating H. pylori infection enhanced the effectiveness of acitretin therapy and shortened response times. Our results suggest that H. pylori infection plays a role in the severity of psoriasis, and that eradicating such infections enhances the effectiveness of psoriasis treatment.
authors: Department of Dermatology, Bezmialem Vakif University School of Medicine, Vatan Caddesi Fatih, 34093 Istanbul, Turkey. nonarir2011@hotmail.com
authors: Nahide
authors: N
authors: Onsun
authors: Hande
authors: H
authors: Arda Ulusal
authors: Ozlem
authors: O
authors: Su
authors: Ismet
authors: I
authors: Beycan
authors: Dilek
authors: D
authors: Biyik Ozkaya
authors: Mustafa
authors: M
authors: Senocak
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D017255:Acitretin / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D016009:Chi-Square Distribution; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D007641:Keratolytic Agents / Q000627:therapeutic use*; D064747:Lansoprazole; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications* / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D007641:Keratolytic Agents; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D017255:Acitretin